Abstract: The invention provides a method for determining a genetic predisposition to prostate cancer in a male human subject. In one aspect, the method comprises determining whether the subject has the genotype GG of refSNP rs125555, where the genotype GG of refSNP rs125555 indicates that the subject is genetically predisposed to prostate cancer.

Abstract: The present invention provides a method of modulating TGF-? activity in a subject. Methods of the present invention comprise administering to the subject an effective amount of a compound of the formula: or a salt, prodrug, tautomer, hydrate, solvate, or stereoisomer thereof, wherein a is an integer from 0 to 4; each R1 is independently hydroxy, alkoxy, halide, alkyl, cyano, nitro, amino, monoalkylamino, dialkylamino, or carboxy; R2 is aryl, cycloalkyl, alkenyl, or alkyl, each of which is optionally substituted; each of X1 and X2 is independently O, S or NR, wherein R3is hydrogen or alkyl; X3 is hydrogen, alkoxy, alkyl, hydroxy, halide, amino, monoalkylamino, or dialkylamino; and X4 is alkoxy, hydroxy, halide, amino, monoalkylamino, or dialkylamino.

Abstract: The present invention provides a method for detecting adverse reaction susceptibility and/or severity risk to an HMG CoA reductase inhibitor by determining the genotype of a CYP3A gene of a subject.